StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Zolgensma Group (onasemnogene abeparvovec by Quarter

Zolgensma Group (onasemnogene abeparvovec — gene therapy for spinal muscular atrophy SMA) ($M)

QuarterlyAnnual

Novartis Zolgensma Group (onasemnogene abeparvovec: $404M in Q3 2026, up 34.2% from a year earlier. That is the highest of the 29 quarters on record here.

Latest, Q3 2026
404
Period ended Sep 30, 2026
Change on a year earlier
+34.2%
301 in Q3 2025
History
29 quarters
Since Q2 2019
Sources
21
Documents cited below

Where the Q3 2026 figure comes from

“|| Zolgensma Group | 404 | 301 | 34 | 35”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedZolgensma Group (onasemnogene abeparvovec — gene therapy for spinal muscular atrophy SMA) ($M)Year on yearSource
Q3 2026Sep 30, 2026404+34.2%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 2026365+22.9%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 2026302-7.6%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 2025307+17.2%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 2025301-2.3%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2025Jun 30, 2025297-14.9%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2025Mar 31, 2025327+10.8%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2024Dec 31, 2024262-8.4%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2024Sep 30, 20243080.0%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2024Jun 30, 2024349+12.2%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2024Mar 31, 2024295-4.5%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2023Dec 31, 2023286-7.4%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2023Sep 30, 2023308-3.4%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2023Jun 30, 2023311-17.9%Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2023Mar 31, 2023309-14.9%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2022Dec 31, 2022309-9.6%Novartis Form 6-K (0001370368-24-000007) ↗

Breakdown

What makes up zolgensma Group (onasemnogene abeparvovec

Cite this data

StockData. (2026). Novartis Zolgensma Group (onasemnogene abeparvovec ($M), quarterly Q2 2019–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-zolgensma-group

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.